Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Verve Therapeutics

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Leadership Update
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Updates on its PCSK9 Program
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer
From Verve Therapeutics
Via GlobeNewswire
Tickers VERV
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.